Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9556 |
High Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.8889 |
High Similarity |
NPD7390 |
Discontinued |
0.8741 |
High Similarity |
NPD1470 |
Approved |
0.8531 |
High Similarity |
NPD5405 |
Approved |
0.8531 |
High Similarity |
NPD5404 |
Approved |
0.8531 |
High Similarity |
NPD5406 |
Approved |
0.8531 |
High Similarity |
NPD5408 |
Approved |
0.8444 |
Intermediate Similarity |
NPD1201 |
Approved |
0.844 |
Intermediate Similarity |
NPD943 |
Approved |
0.8302 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.8228 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.8105 |
Intermediate Similarity |
NPD3226 |
Approved |
0.8082 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.8077 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8069 |
Intermediate Similarity |
NPD1607 |
Approved |
0.8013 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7961 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7961 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7961 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7959 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7937 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7931 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7885 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7868 |
Intermediate Similarity |
NPD405 |
Clinical (unspecified phase) |
0.7843 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7843 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7843 |
Intermediate Similarity |
NPD2534 |
Approved |
0.78 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7718 |
Intermediate Similarity |
NPD3299 |
Clinical (unspecified phase) |
0.7707 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7683 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7682 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7667 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7643 |
Intermediate Similarity |
NPD3019 |
Approved |
0.764 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7616 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7616 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7616 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7562 |
Intermediate Similarity |
NPD2801 |
Approved |
0.755 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7548 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7545 |
Intermediate Similarity |
NPD6020 |
Phase 2 |
0.7531 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7518 |
Intermediate Similarity |
NPD2932 |
Approved |
0.7516 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7484 |
Intermediate Similarity |
NPD3300 |
Phase 2 |
0.7483 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7469 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7469 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7453 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7452 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7447 |
Intermediate Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.744 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7439 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7434 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7434 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7432 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7403 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7386 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7375 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7355 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7353 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7351 |
Intermediate Similarity |
NPD6651 |
Approved |
0.733 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7299 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7284 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7279 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7273 |
Intermediate Similarity |
NPD1471 |
Phase 3 |
0.7262 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7262 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7262 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7255 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7246 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7246 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7244 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD3026 |
Approved |
0.7222 |
Intermediate Similarity |
NPD3023 |
Approved |
0.7215 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7214 |
Intermediate Similarity |
NPD5951 |
Approved |
0.7212 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7209 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7208 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7205 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7203 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7203 |
Intermediate Similarity |
NPD3025 |
Approved |
0.7203 |
Intermediate Similarity |
NPD3024 |
Approved |
0.7197 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7176 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7151 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7151 |
Intermediate Similarity |
NPD6535 |
Approved |
0.7151 |
Intermediate Similarity |
NPD6534 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7091 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7086 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7086 |
Intermediate Similarity |
NPD3268 |
Approved |
0.708 |
Intermediate Similarity |
NPD2342 |
Discontinued |
0.7071 |
Intermediate Similarity |
NPD7635 |
Approved |
0.707 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7069 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7049 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7049 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7049 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7049 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7049 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7049 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7049 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7035 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7033 |
Intermediate Similarity |
NPD7700 |
Phase 2 |
0.7033 |
Intermediate Similarity |
NPD7699 |
Phase 2 |
0.703 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7029 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7029 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7029 |
Intermediate Similarity |
NPD9266 |
Approved |
0.7029 |
Intermediate Similarity |
NPD74 |
Approved |
0.7027 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7022 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD3972 |
Approved |
0.7 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.6994 |
Remote Similarity |
NPD7074 |
Phase 3 |
0.6993 |
Remote Similarity |
NPD9493 |
Approved |
0.6989 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6989 |
Remote Similarity |
NPD8319 |
Approved |
0.6988 |
Remote Similarity |
NPD8438 |
Clinical (unspecified phase) |
0.6982 |
Remote Similarity |
NPD1247 |
Approved |
0.6975 |
Remote Similarity |
NPD920 |
Approved |
0.6975 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.697 |
Remote Similarity |
NPD37 |
Approved |
0.6966 |
Remote Similarity |
NPD1651 |
Approved |
0.6963 |
Remote Similarity |
NPD846 |
Approved |
0.6963 |
Remote Similarity |
NPD940 |
Approved |
0.6957 |
Remote Similarity |
NPD9264 |
Approved |
0.6957 |
Remote Similarity |
NPD9263 |
Approved |
0.6957 |
Remote Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD9267 |
Approved |
0.6941 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6936 |
Remote Similarity |
NPD7286 |
Phase 2 |
0.6936 |
Remote Similarity |
NPD7054 |
Approved |
0.6935 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.6935 |
Remote Similarity |
NPD7697 |
Approved |
0.6935 |
Remote Similarity |
NPD7698 |
Approved |
0.6935 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6931 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6928 |
Remote Similarity |
NPD6663 |
Approved |
0.6918 |
Remote Similarity |
NPD7163 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD8166 |
Discontinued |
0.6918 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6913 |
Remote Similarity |
NPD1876 |
Approved |
0.6906 |
Remote Similarity |
NPD6212 |
Phase 3 |
0.6906 |
Remote Similarity |
NPD6213 |
Phase 3 |
0.6906 |
Remote Similarity |
NPD6214 |
Clinical (unspecified phase) |
0.6898 |
Remote Similarity |
NPD7871 |
Phase 2 |
0.6898 |
Remote Similarity |
NPD7870 |
Phase 2 |
0.6897 |
Remote Similarity |
NPD7472 |
Approved |
0.6892 |
Remote Similarity |
NPD4878 |
Approved |
0.6889 |
Remote Similarity |
NPD1242 |
Phase 1 |
0.6887 |
Remote Similarity |
NPD5736 |
Approved |
0.6886 |
Remote Similarity |
NPD5402 |
Approved |
0.6867 |
Remote Similarity |
NPD1203 |
Approved |
0.6864 |
Remote Similarity |
NPD6234 |
Discontinued |
0.6863 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6857 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6852 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6852 |
Remote Similarity |
NPD642 |
Clinical (unspecified phase) |
0.6845 |
Remote Similarity |
NPD4965 |
Approved |
0.6845 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.6845 |
Remote Similarity |
NPD4966 |
Approved |
0.6842 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6836 |
Remote Similarity |
NPD5035 |
Approved |
0.6832 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6825 |
Remote Similarity |
NPD6973 |
Clinical (unspecified phase) |
0.6824 |
Remote Similarity |
NPD1281 |
Approved |
0.6821 |
Remote Similarity |
NPD5033 |
Approved |
0.6818 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6815 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.6815 |
Remote Similarity |
NPD3020 |
Approved |
0.681 |
Remote Similarity |
NPD6273 |
Approved |
0.6803 |
Remote Similarity |
NPD4626 |
Approved |
0.68 |
Remote Similarity |
NPD4956 |
Approved |
0.6789 |
Remote Similarity |
NPD7701 |
Phase 2 |
0.6782 |
Remote Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.6782 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6782 |
Remote Similarity |
NPD7177 |
Discontinued |
0.6781 |
Remote Similarity |
NPD9545 |
Approved |
0.6781 |
Remote Similarity |
NPD3091 |
Approved |
0.678 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.678 |
Remote Similarity |
NPD5032 |
Approved |
0.678 |
Remote Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.6772 |
Remote Similarity |
NPD7211 |
Clinical (unspecified phase) |
0.6771
|
Remote Similarity |
NPD7801 |
Approved |